Open AccessVericiguat in Patients with Heart Failure and Reduced Ejection Fraction
Author(s) -
Paul W. Armstrong,
Burkert Pieske,
Kevin J. Anstrom,
Justin A. Ezekowitz,
Adrian F. Hernandez,
Javed Butler,
Carolyn S.P. Lam,
Piotr Ponikowski,
Adriaan A. Voors,
Gang Jia,
Steven E. McNulty,
Mahesh J. Patel,
Lothar Roessig,
Joerg Koglin,
Christopher M. O’Connor
Publication year - 2020
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1915928
Subject(s) - ejection fraction , heart failure , cardiology , fraction (chemistry) , medicine , chemistry , organic chemistry
The effect of vericiguat, a novel oral soluble guanylate cyclase stimulator, in patients with heart failure and reduced ejection fraction who had recently been hospitalized or had received intravenous diuretic therapy is unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom